Indicated for the treatment of foregut, midgut and hindgut neuroendocrine tumors, the radiopharmaceutical Bravnetsa is reportedly bioequivalent and therapeutically equivalent to the previously FDA-approved Lutathera.
|Articles|November 23, 1994
Boston Scientific to buy Scimed
Interventional firms Boston Scientificand Scimed Life Systems have announced a plan to merge. Accordingto an agreement signed between the companies, Boston Scientific,of Watertown, MA, would acquire Maple Grove, MN-based Scimed ina stock swap in which
Advertisement
Interventional firms Boston Scientificand Scimed Life Systems have announced a plan to merge. Accordingto an agreement signed between the companies, Boston Scientific,of Watertown, MA, would acquire Maple Grove, MN-based Scimed ina stock swap in which 3.4152 shares of Boston Scientific stockwould be exchanged for each Scimed share. Scimed will operateas a subsidiary of Boston Scientific. Boston Scientific boughtCardiovascular Imaging Systems (CVIS) earlier this year (SCAN9/14/94).
Advertisement
Related to this article
Newly cleared findings for the adjunctive AI platform a2z-Abdo-Triage include acute appendicitis, renal traumatic injury, ureteral stone and retroperitoneal hematoma.
In multivariable external testing, tumor structure habitat phenotypes from pre-treatment MRI revealed more than a doubling of recurrence risk for women with stage 2 and stage 3 breast cancer.
Could a la carte pricing be a consideration in improving revenue for radiologists in private practice?
Catch up on a variety of FDA news in radiology from the past week.
Catch up on the top radiology content of the past week.
Reportedly one of the first FDA-cleared chest X-ray AI software platforms derived from a foundation model, the Chest Xray software facilitates detection and localization of lung nodules, pneumothorax, mediastinal abnormalities and other thoracic abnormalities.
Incorporating structural MRI to improve PET imaging resolution, the MICSI-PET software also offers automated Centiloid quantification from amyloid PET scans.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears Software That Combines MRI Enhancement of PET Imaging with Automated Quantification of Amyloid and Tau PET
2
Can MRI-Derived Tumor Habitat Subregions Bolster Recurrence Risk Stratification in Stage 2 and 3 Breast Cancer Cases?
3
FDA Clears AI-Powered Triage Software for 10 Findings on Abdominopelvic CT
4
Diagnostic Imaging’s Weekly Scan: September 13 — September 19
5